Serious infection risk after 1 year between patients with rheumatoid arthritis treated with rituximab or with a second TNFi after initial TNFi failure: results from The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis

OBJECTIVES: Both TNF inhibitors (TNFi) and rituximab (RTX), a B-cell depleting biologic, can disrupt the immune system in RA. RTX is licensed in Europe for use following TNFi failure. However, safety data on serious infections (SIs) are scarce for RTX in daily practice. This analysis aims to compare...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Rheumatology (Oxford)
Главные авторы: Silva-Fernández, Lucía, De Cock, Diederik, Lunt, Mark, Low, Audrey S, Watson, Kath D, Symmons, Deborah P M, Hyrich, Kimme L
Формат: Artigo
Язык:Inglês
Опубликовано: Oxford University Press 2018
Предметы:
Clinical Science
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6105920/
https://ncbi.nlm.nih.gov/pubmed/28968862
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/rheumatology/kex304
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы